The passing of J. Craig Venter in April 2026 serves as a profound catalyst for a global reassessment of how humanity interacts with the fundamental building blocks of existence, moving beyond the era of genetic discovery into one of active biological fabrication. Throughout his career, Venter
The biopharmaceutical industry is witnessing a fundamental departure from passive pharmaceutical agents to complex, programmable biological machines that actively navigate the human body. This shift marks the rise of multifunctional Chimeric Antigen Receptor (CAR) T-cell therapy, a modality that
Signals from a pivotal trial now cut through the noise of a crowded obesity market, forcing hard questions about where dual agonists belong and how quickly they can reshape care. Obesity has shifted from a lifestyle narrative to a biologic disease with organ-level consequences, most notably in the
Matthias Aizenberg sits down with Ivan Kairatov, a biopharma expert whose work straddles gene editing and viral delivery, to unpack a new way of building better gene-editing vehicles by rethinking the cells that make them. Rather than only re-engineering virus-like particles, his team interrogated
The landscape of global pharmaceuticals is currently witnessing a profound architectural shift as legacy regulatory frameworks, once characterized by redundant clinical hurdles, give way to a streamlined, evidence-based approach designed to democratize access to biological therapies. For several
The recent breakthrough in oncological research has shifted the paradigm from analyzing what a tumor is composed of to understanding exactly how its internal components are physically positioned. Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified that the spatial
